Comparative Pharmacology
Head-to-head clinical analysis: BIAXIN XL versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIAXIN XL versus ZMAX.
BIAXIN XL vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clarithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
500 mg orally once daily for 7 to 14 days
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal elimination half-life is 5-7 hours in healthy adults; prolonged to 20-40 hours in patients with severe hepatic impairment (Child-Pugh Class C).
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Approximately 20-30% of the dose is excreted unchanged in urine, with the remainder as metabolites (primarily via biliary/fecal elimination). Renal clearance accounts for about 12% of total clearance.
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic